Lysogene is committed to developing and commercializing safe and effective gene therapy products for patients living with serious, life-threatening, rare diseases. We appreciate the responsibility of bringing these innovative products to patients, and this commitment drives our work each day. We believe in the importance of collaborating closely with patient, medical and regulatory communities to help achieve this goal.
The primary mechanism for access to investigational therapies is by participation in a clinical study. Clinical studies collect the information necessary to understand the safety and efficacy of the potential therapy allowing for regulatory authority review and potential approval. Ultimately, approval by regulatory authorities gives the opportunity for the broadest access by allowing physicians to prescribe the therapy to any patient who might benefit.
For information on ongoing Lysogene clinical studies: visit ClinicalTrials.gov and search registered clinical studies for mucopolysaccharidosis type IIIA or GM1 gangliosidosis. If you locate a clinical study with a participating site that you are interested in, you or your physician may contact that site directly for more information.
We understand that patients and families may be interested in accessing our investigational therapies prior to regulatory approval and outside of the clinical trial setting, through compassionate use programs, sometimes called “early access” or in the United States, Expanded Access.
After much consideration, we have determined that, at this point in time, we are unable to offer a compassionate use program for mucopolysaccharidosis type IIIA (LYS-SAF302) or for GM1 gangliosidosis (LYS-GM101). We will continue to evaluate the possibility of compassionate use and we will update the community if any such programs can be conducted in a fair and sustainable way without compromising clinical development and potential regulatory approval. While it is recommended that queries be made through treating physicians; for additional information, contact the Lysogene Patient Access group.